TY  - JOUR
A1  - Kelm, M.
A1  - Seyfried, F.
A1  - Reimer, S.
A1  - Krajinovic, K.
A1  - Miras, A. D.
A1  - Jurowich, C.
A1  - Germer, C. T.
A1  - Brand, M.
T1  - Proximal jejunal stoma as ultima ratio in case of traumatic distal duodenal perforation facilitating successful EndoVAC\(^{®}\) treatment: a case report
JF  - International Journal of Surgery Case Reports
N2  - Introduction:
During damage control surgery for blunt abdominal traumata simultaneous duodenal perforations can be missed making secondary sufficient surgical treatment challenging. Endoluminal vacuum (EndoVAC™) therapy has been shown to be a revolutionary option but has anatomical and technical limits.

Presentation of the case:
A 59-year old man with hemorrhagic shock due to rupture of the mesenteric root after blunt abdominal trauma received damage control treatment. Within a scheduled second-look, perforation of the posterior duodenal wall was identified. Due to local and systemic conditions, further surgical treatment was limited. Decision for endoscopic treatment was made but proved to be difficult due to the distal location. Finally, double-barreled jejunal stoma was created for transstomal EndoVAC™ treatment. Complete leakage healing was achieved and jejunostomy reversal followed subsequently.

Discussion:
During damage control surgery simultaneous bowel injuries can be missed leading to life-threatening complications with limited surgical options. EndoVAC™ treatment is an option for gastrointestinal perforations but has anatomical limitations that can be sufficiently shifted by a transstomal approach for intestinal leakage.

Conclusion:
In trauma related laparotomy complete mobilization of the duodenum is crucial. As ultima ratio, transstomal EndoVAC™ is a safe and feasible option and can be considered for similar cases.
KW  - transstomal endoluminal vacuum therapy
KW  - EndoVAC and small bowel
KW  - duodenal trauma
KW  - duodenal perforation
Y1  - 2017
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-159292
VL  - 41
ER  - 
TY  - JOUR
A1  - Alepee, Natalie
A1  - Bahinski, Anthony
A1  - Daneshian, Mardas
A1  - De Weyer, Bart
A1  - Fritsche, Ellen
A1  - Goldberg, Alan
A1  - Hansmann, Jan
A1  - Hartung, Thomas
A1  - Haycock, John
A1  - Hogberg, Helena T.
A1  - Hoelting, Lisa
A1  - Kelm, Jens M.
A1  - Kadereit, Suzanne
A1  - McVey, Emily
A1  - Landsiedel, Robert
A1  - Leist, Marcel
A1  - Lübberstedt, Marc
A1  - Noor, Fozia
A1  - Pellevoisin, Christian
A1  - Petersohn, Dirk
A1  - Pfannenbecker, Uwe
A1  - Reisinger, Kerstin
A1  - Ramirez, Tzutzuy
A1  - Rothen-Rutishauser, Barbara
A1  - Schäfer-Korting, Monika
A1  - Zeilinger, Katrin
A1  - Zurich, Marie-Gabriele
T1  - State-of-the-Art of 3D Cultures (Organs-on-a-Chip) in Safety Testing and Pathophysiology
JF  - ALTEX - Alternatives to Animal Experimentation
N2  - Integrated approaches using different in vitro methods in combination with bioinformatics can (i) increase the success rate and speed of drug development; (ii) improve the accuracy of toxicological risk assessment; and (iii) increase our understanding of disease. Three-dimensional (3D) cell culture models are important building blocks of this strategy which has emerged during the last years. The majority of these models are organotypic, i.e., they aim to reproduce major functions of an organ or organ system. This implies in many cases that more than one cell type forms the 3D structure, and often matrix elements play an important role. This review summarizes the state of the art concerning commonalities of the different models. For instance, the theory of mass transport/metabolite exchange in 3D systems and the special analytical requirements for test endpoints in organotypic cultures are discussed in detail. In the next part, 3D model systems for selected organs liver, lung, skin, brain are presented and characterized in dedicated chapters. Also, 3D approaches to the modeling of tumors are presented and discussed. All chapters give a historical background, illustrate the large variety of approaches, and highlight up- and downsides as well as specific requirements. Moreover, they refer to the application in disease modeling, drug discovery and safety assessment. Finally, consensus recommendations indicate a roadmap for the successful implementation of 3D models in routine screening. It is expected that the use of such models will accelerate progress by reducing error rates and wrong predictions from compound testing.
KW  - 3D models
KW  - organotypic
KW  - organ-on-a-chip
KW  - multicellular tumor spheroids
KW  - primary human hepatocytes
KW  - embryonic stem cell
KW  - reconstructed human epidermis
KW  - in-vitro models
KW  - full thickness skin
KW  - necrosis-factor-alpha
KW  - metabolic flux analysis
KW  - long-term
KW  - human liver cells
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117826
VL  - 31
IS  - 4
ER  -